A combination of CPI-613 and chloroquine significantly suppressed tumor... | Download Scientific Diagram
Devimistat (CPI-613) (Devimistat) | CAS 95809-78-2 | AbMole BioScience | Devimistat (CPI-613) Price
Mitochondrial Matrix Protease ClpP Agonists inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis | bioRxiv
The Mitochondrion as an Emerging Therapeutic Target in Cancer: Trends in Molecular Medicine
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
CPI-613 Supplier | CAS 95809-78-2 | Focus Biomolecules
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation | Scientific Reports
ラファエルホールディングスの適時開示・その他 | 米国株｜株探（かぶたん) - 株探
Devimistat (CPI-613) | デヒドロゲナーゼ 阻害剤
Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts | Scientific Reports
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process | SpringerLink
Devimistat – Drug Approvals International
Selectively Targeting Metabolism in Mitochondria In Cancer Cells | Cancer Biology
CPI-613 | CAS:95809-78-2 | PDH/α-KGDH inhibitor | High Purity | Manufacturer BioCrick
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling | Journal of Experimental & Clinical Cancer Research | Full Text
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? | Oncotarget
Mitochondria in cancer metabolism, an organelle whose time has come? - Abstract - Europe PMC
Devimistat | CPI-613 | CAS#95809-78-2 | Antineoplastic | MedKoo Biosciences
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling | Journal of Experimental & Clinical Cancer Research | Full Text
CPI-613 induces reactive oxygen species-mediated glutathionylation and... | Download Scientific Diagram
Prolongation of survival induced by four doses of CPI-613 (25 mg/kg),... | Download Scientific Diagram
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study | Future Oncology
